You are now leaving the ViiV Healthcare website and being re-directed to an external website

Explore ViiV Healthcare

I am a

... looking for

US News

Local Stories

IDWeek 2019: ViiV Healthcare to present 20 abstracts from its innovative R&D portfolio with focus on 2-drug and long-acting regimens and mental health impact of HIV

02 Oct 2019
ViiV Healthcare reports positive phase III study results of investigational, long-acting, injectable HIV-treatment regimen administered every two months

22 Aug 2019
ViiV Healthcare submits regulatory application to European Medicines Agency for investigational cabotegravir to be used in combination with rilpivirine as the first monthly injectable treatment for HIV

29 Jul 2019
ViiV Healthcare announces positive Week 48 results in first study to evaluate treatment switch from TAF-containing regimen with three or more drugs to 2-drug regimen of dolutegravir/lamivudine for HIV-1 infection

24 Jul 2019
ViiV Healthcare presents GEMINI 1 & 2 studies through Week 96 showing 2-drug regimen of dolutegravir plus lamivudine continues to demonstrate high efficacy rates and no cases of treatment emergent resistance

24 Jul 2019
ViiV Healthcare presents positive 96-week data from phase III study of investigational fostemsavir in heavily treatment-experienced patients with HIV at IAS 2019

22 Jul 2019
IAS 2019: ViiV Healthcare showcasing innovation in HIV science

15 Jul 2019
ViiV Healthcare announces phase III study meets primary endpoint, demonstrating the ability to control HIV-1 with a 2-drug regimen of dolutegravir plus lamivudine in virally suppressed patients switching from a TAF-containing, 3-drug regimen

10 Jul 2019
ViiV Healthcare announces start of first-ever study to identify and evaluate approaches to implementing its once-monthly injectable HIV treatment in clinical practice

08 Jul 2019
ViiV Healthcare submits New Drug Application to US FDA for the first monthly, injectable, two-drug regimen of cabotegravir and rilpivirine for treatment of HIV

30 Apr 2019
US FDA approves ViiV Healthcare’s Dovato (dolutegravir/lamivudine), the first, once-daily, single-tablet, two-drug regimen for treatment-naïve HIV-1 adults

09 Apr 2019

ViiV Healthcare announces positive phase 3 results from the BRIGHTE study of fostemsavir in heavily treatment-experienced patients with HIV

31 Oct 2018
ViiV Healthcare reports positive 48-week results for second phase III study for novel, long-acting, injectable HIV-treatment regimen

30 Oct 2018
ViiV Healthcare presents three-year data for investigational long-acting injectable, two-drug HIV regimen

29 Oct 2018
ViiV Healthcare reports positive 48-week results for first pivotal, phase III study for novel, long-acting, injectable HIV-treatment regimen

15 Aug 2018
ViiV Healthcare announces SWORD 100-week data for Juluca (dolutegravir/rilpivirine) at AIDS 2018

24 Jul 2018
ViiV Healthcare presents phase III data showing two drug regimen has similar efficacy to a three-drug regimen in treatment naïve HIV patients, with no resistance

24 Jul 2018
ViiV Healthcare shares data from landmark 2-drug regimen trials at AIDS 2018

18 Jul 2018
ViiV Healthcare announces positive new dolutegravir data for the treatment of people living with HIV co-infected with tuberculosis

05 Mar 2018

ViiV Healthcare announces dolutegravir data from INSPIRING study for the treatment of people living with HIV co-infected with tuberculosis.
ViiV Healthcare files patent infringement litigation against Gilead Sciences Inc. over bictegravir

08 Feb 2018
ViiV Healthcare launches eighth phase III study in two- drug regimen programme for HIV-1 treatment

08 Feb 2018
ViiV Healthcare announces start of phase III study of long-acting cabotegravir for HIV prevention in women

30 Nov 2017
ViiV Healthcare starts third phase III HIV treatment study investigating long-acting two-drug regimen of cabotegravir plus rilpivirine

27 Nov 2017
ViiV Healthcare announces US FDA approval for Juluca®

21 Nov 2017

ViiV Healthcare announces FDA drug approval for Juluca® as the first 2-drug, once-daily, single pill for maintenance treatment in virologically suppressed.
ViiV Healthcare announces positive phase 3 results from the BRIGHTE study of fostemsavir in heavily treatment-experienced patients with HIV

26 Oct 2017
New results from the Positive Perspectives global survey provide insights into the attitudes and perceptions of people living with HIV

25 Oct 2017
ViiV Healthcare Awards $1 Million In Grants For Positive Action For Women In The U.S.

05 Sep 2017

ViiV Healthcare awards $1 million in grants for Positive Action programs for women to support innovative, forward-thinking community collaborations to end stigma.
ViiV Healthcare Expands U.S. Commitment to Youth Living With HIV Through Its Positive Action Program

08 Aug 2017
ViiV Healthcare and NEAT-ID announce results from the NEAT 022 study at the International AIDS Society meeting in Paris

25 Jul 2017
ViiV Healthcare announces superior efficacy of dolutegravir versus lopinavir/ritonavir in second-line HIV treatment in resource-limited settings

25 Jul 2017
Phase II study results showed comparable viral suppression rates at 96 weeks for a two-drug regimen

24 Jul 2017
ViiV Healthcare shares data from its innovative portfolio with HIV community at IAS 2017

20 Jul 2017
ViiV Healthcare submits regulatory applications for the first HIV maintenance regimen comprising only two medicines

01 Jun 2017
ViiV Healthcare Announces FDA Approval of SELZENTRY® (maraviroc) for Use in Children and Adolescents Living With HIV

10 Nov 2016
ViiV Healthcare extends Medicines Patent Pool licence agreement for dolutegravir to cover all lower middle-income countries

25 Apr 2016
ViiV Healthcare announces first phase II HIV prevention study results for investigational long-acting injectable cabotegravir

24 Feb 2016

ViiV Healthcare announces ECLAIR HIV prevention study results for investigational long-acting injectable cabotegravir. Find out more about the study results.
ViiV Healthcare announces phase II study results for first two drug, long-acting injectable regimen for HIV-1 treatment

23 Feb 2016

ViiV Healthcare announces LATTE-2 study results for the first investigational two drug, long-acting injectable regimen for HIV-1 treatment at CROI in Boston. Find out more.
ViiV Healthcare to progress collaboration with Janssen to develop the first long-acting, two drug injectable regimen for treatment of HIV

07 Jan 2016

Website images are not intended to imply that the models pictured have HIV.

©2018 ViiV Healthcare group of companies. All rights reserved. ViiV Healthcare US, Five Moore Drive, Research Triangle Park, North Carolina USA, 27709-3398.

Connect with us